Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZKYIV)

Drug Name
Amsacrine Drug Info
Synonyms
Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
2179
ChEBI ID
CHEMBL43
CAS Number
CAS 51264-14-3
TTD Drug ID
D0G9YH
VARIDT Drug ID
DR00917
INTEDE Drug ID
DR0109

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.43 0.00e+0 63/73 (86.3%) CDKN1A;DDB2;TNFRSF10B;...
Graft-versus-host disease 2.12 0.00e+0 32/42 (76.19%) FAS;IL1B;HLA-B;...
NF-kappa B signaling pathway 2.11 0.00e+0 90/104 (86.54%) RELB;CXCL8;GADD45A;...
Influenza A 2.08 0.00e+0 156/172 (90.7%) TNFRSF10B;FAS;CXCL8;...
Epstein-Barr virus infection 2.06 0.00e+0 189/202 (93.56%) CDKN1A;DDB2;RELB;...
Viral protein interaction with cytokine and cytokine re... 2.05 0.00e+0 84/100 (84%) TNFRSF10B;CXCL8;CXCL2;...
Oxidative phosphorylation 2.04 0.00e+0 93/133 (69.92%) NDUFB1;ATP6V1D;ATP6V1E1;...
Cytokine-cytokine receptor interaction 2.03 0.00e+0 246/295 (83.39%) TNFRSF10B;FAS;GDF15;...
Rheumatoid arthritis 2.03 0.00e+0 78/93 (83.87%) CXCL8;CXCL2;IL1B;...
Herpes simplex virus 1 infection 2.00 0.00e+0 165/498 (33.13%) FAS;TAP1;BIRC3;...
TNF signaling pathway 2.00 0.00e+0 103/112 (91.96%) FAS;CXCL2;BIRC3;...
Necroptosis 1.99 0.00e+0 113/159 (71.07%) TNFRSF10B;FAS;BIRC3;...
Type I diabetes mellitus 1.94 0.00e+0 38/43 (88.37%) FAS;IL1B;HLA-B;...
Measles 1.92 0.00e+0 133/139 (95.68%) FAS;IL1B;MX1;...
IL-17 signaling pathway 1.92 0.00e+0 84/94 (89.36%) CXCL8;CXCL2;IL1B;...
NOD-like receptor signaling pathway 1.91 6.74e-4 145/181 (80.11%) CXCL8;CXCL2;BIRC3;...
Cytosolic DNA-sensing pathway 1.89 6.35e-4 52/63 (82.54%) IL1B;IRF7;NFKBIA;...
Kaposi sarcoma-associated herpesvirus infection 1.89 1.20e-3 172/193 (89.12%) CDKN1A;FAS;CXCL8;...
Hepatitis C 1.87 1.70e-3 139/157 (88.54%) CDKN1A;FAS;MX1;...
Autoimmune thyroid disease 1.86 1.62e-3 46/53 (86.79%) FAS;HLA-B;HLA-F;...
Glioma 1.83 4.11e-3 67/75 (89.33%) CDKN1A;DDB2;GADD45A;...
Allograft rejection 1.81 4.90e-3 32/38 (84.21%) FAS;HLA-B;HLA-F;...
Non-alcoholic fatty liver disease 1.81 5.16e-3 126/155 (81.29%) FAS;CXCL8;IL1B;...
Chronic myeloid leukemia 1.80 7.64e-3 72/76 (94.74%) CDKN1A;DDB2;GADD45A;...
Viral myocarditis 1.80 7.77e-3 53/60 (88.33%) CXADR;HLA-B;HLA-F;...
Small cell lung cancer 1.78 7.89e-3 90/92 (97.83%) CDKN1A;DDB2;GADD45A;...
Hepatitis B 1.76 1.04e-2 151/162 (93.21%) CDKN1A;DDB2;FAS;...
Basal cell carcinoma 1.73 1.39e-2 41/63 (65.08%) CDKN1A;DDB2;GADD45A;...
Pathways of neurodegeneration 1.72 1.49e-2 354/475 (74.53%) FAS;IL1B;GPX1;...
Parkinson disease 1.72 1.57e-2 176/249 (70.68%) BAX;PPIF;NDUFB1;...
Other types of O-glycan biosynthesis -1.75 3.64e-2 29/47 (61.7%) POMT1;GALNT11;GALNT2;...
Cell cycle -1.90 3.64e-3 110/124 (88.71%) CDC23;SMAD4;ANAPC10;...
Protein processing in endoplasmic reticulum -1.90 0.00e+0 127/171 (74.27%) MAN1A2;DDOST;DNAJA1;...
Spliceosome -1.96 0.00e+0 101/150 (67.33%) LSM7;SF3B1;AQR;...
Progesterone-mediated oocyte maturation -1.96 0.00e+0 75/100 (75%) PKMYT1;GNAI3;ANAPC2;...
Oocyte meiosis -2.15 0.00e+0 90/129 (69.77%) PPP3CB;YWHAH;PKMYT1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 100uM 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM - 100uM 6H, 48H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 3.33uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H